RS67793B1 - Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida - Google Patents

Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida

Info

Publication number
RS67793B1
RS67793B1 RS20260155A RSP20260155A RS67793B1 RS 67793 B1 RS67793 B1 RS 67793B1 RS 20260155 A RS20260155 A RS 20260155A RS P20260155 A RSP20260155 A RS P20260155A RS 67793 B1 RS67793 B1 RS 67793B1
Authority
RS
Serbia
Prior art keywords
riazaspiro
difluorobenzyl
carbaldehyde
methylcyclohexyl
nonane
Prior art date
Application number
RS20260155A
Other languages
English (en)
Inventor
Chihyuan Chuang
Xiaolin Wang
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of RS67793B1 publication Critical patent/RS67793B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
RS20260155A 2022-09-02 2023-09-01 Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida RS67793B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022116765 2022-09-02
EP23783204.3A EP4581034B1 (en) 2022-09-02 2023-09-01 Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
PCT/US2023/073355 WO2024050539A1 (en) 2022-09-02 2023-09-01 Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde

Publications (1)

Publication Number Publication Date
RS67793B1 true RS67793B1 (sr) 2026-03-31

Family

ID=88237593

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260155A RS67793B1 (sr) 2022-09-02 2023-09-01 Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida

Country Status (20)

Country Link
US (1) US20240132498A1 (sr)
EP (2) EP4581034B1 (sr)
JP (1) JP2025530739A (sr)
KR (1) KR20250119513A (sr)
CN (1) CN119998292A (sr)
AR (1) AR130380A1 (sr)
AU (1) AU2023333281A1 (sr)
CA (1) CA3266046A1 (sr)
CL (1) CL2025000524A1 (sr)
DK (1) DK4581034T3 (sr)
FI (1) FI4581034T3 (sr)
HR (1) HRP20260158T1 (sr)
IL (1) IL319137A (sr)
LT (1) LT4581034T (sr)
MX (1) MX2025002531A (sr)
PT (1) PT4581034T (sr)
RS (1) RS67793B1 (sr)
SI (1) SI4581034T1 (sr)
TW (1) TW202423927A (sr)
WO (1) WO2024050539A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) * 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂

Also Published As

Publication number Publication date
CL2025000524A1 (es) 2025-06-23
WO2024050539A1 (en) 2024-03-07
AR130380A1 (es) 2024-12-04
KR20250119513A (ko) 2025-08-07
PT4581034T (pt) 2026-03-12
JP2025530739A (ja) 2025-09-17
EP4725486A2 (en) 2026-04-15
EP4581034B1 (en) 2025-12-24
CA3266046A1 (en) 2024-03-07
IL319137A (en) 2025-04-01
DK4581034T3 (da) 2026-02-09
HRP20260158T1 (hr) 2026-03-27
CN119998292A (zh) 2025-05-13
MX2025002531A (es) 2025-04-02
EP4581034A1 (en) 2025-07-09
LT4581034T (lt) 2026-03-10
TW202423927A (zh) 2024-06-16
US20240132498A1 (en) 2024-04-25
FI4581034T3 (fi) 2026-02-11
SI4581034T1 (sl) 2026-03-31
AU2023333281A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
RS67793B1 (sr) Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida
EP4663641A3 (en) Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
MX2024005335A (es) Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos.
WO2009151997A8 (en) Process for producing bicycloaniline derivatives
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
AU2024254535A1 (en) 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5
WO2000043392A3 (de) Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
MX2025000988A (es) Nueva sal del compuesto de imidazo[1,2-a]piridina, forma cristalina de la misma y metodo de preparacion
IL306083A (en) History of 3H, 4H - thiano[3,2-d]pyrimidin-4-one as TRPA1 inhibitors
EP1048666A4 (en) NOVEL COMPOUNDS HAVING INHIBITOR EFFECT OF cGMP-PDE
HK40126926A (en) Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
IL287887A (en) Synthesis of labeled imidazo[2,1-a]pyrimidines
IL316302A (en) Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
WO2008140646A3 (en) Process for the synthesis of cmhtp and intermediates thereof
AU2022299278A1 (en) Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hemisuccinate
WO2022194909A3 (en) Process for preparing risdiplam
IL310443A (en) PYRAZOLO[3,4-B]PYRIDINE compounds for the treatment of autoimmune disease
EP3634963B8 (en) 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders
IL314082A (en) Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide
HK40103339A (en) Pyrazolo[1,5-a]pyrimidine compound for the treatment of dermal disorders
HK40116990A (en) Method for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compound
HK40120959A (en) Pyrazolo[1,5-a]pyridine derivatives for treating trpm3- mediated disorders
ZA202406459B (en) Pyrido[1,2-a]pyrimidin-4-one derivatives
CA3279710A1 (en) Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3- sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[1,5-a]pyrazine-1-carboxamide and methods for using the same